Kexing Biopharm (688136.SH): GB19 Injection for the treatment of skin lupus erythematosus indications received approval notice for drug clinical trials.

Kexing Biopharm (688136.SH) announced that its wholly-owned subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd. (referred to as "Shenzhen Kexing") has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The National Medical Products Administration has approved Shenzhen Kexing's innovative drug "GB19 Injection" for targeting BDCA2 (blood dendritic cell antigen 2) to conduct clinical trials for the indication of cutaneous lupus erythematosus (CLE). The approval of the clinical trial for GB19 Injection for the indication of cutaneous lupus erythematosus will not have a significant impact on the company's recent financial condition and operational performance. As of the date of this announcement, GB19 Injection has received approval from the National Medical Products Administration to conduct clinical trials for the indications of systemic lupus erythematosus and cutaneous lupus erythematosus. If the development of this drug is successful and it is launched in the future, it will provide a more diverse product range to meet market demand, enrich the company's product portfolio, and further enhance the company's market competitiveness.